Floatz logo

Cetuximab

KRAS G12S Mutation

Kumquat Biosciences Inc.monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the KRAS G12S Mutation cohort.

Asset / SponsorPhaseRating
kqb198
Kumquat Biosciences Inc.
Phase 1CC
kqb365
Kumquat Biosciences Inc.
Phase 1CC

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →